Pluri (NASDAQ:PLUR) and Cytokinetics (NASDAQ:CYTK) Head to Head Comparison

Cytokinetics (NASDAQ:CYTK) and Pluri (NASDAQ:PLUR) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Profitability

This table compares Cytokinetics and Pluri’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-1,321.12%	N/A	-51.01%
Pluri	-2,344.59%	N/A	-82.71%

Earnings & Valuation

This table compares Cytokinetics and Pluri”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$67.67 million	120.63	-$784.96 million	($7.22)	-9.09
Pluri	$1.02 million	12.27	-$23.82 million	($2.45)	-0.41

Pluri has lower revenue, but higher earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Cytokinetics and Pluri, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1	1	18	0	2.85
Pluri	1	0	0	0	1.00

Cytokinetics presently has a consensus target price of $106.00, suggesting a potential upside of 61.59%. Given Cytokinetics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Cytokinetics is more favorable than Pluri.

Institutional & Insider Ownership

16.6% of Pluri shares are held by institutional investors. 2.6% of Cytokinetics shares are held by company insiders. Comparatively, 43.2% of Pluri shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Cytokinetics has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Comparatively, Pluri has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500.

Summary

Cytokinetics beats Pluri on 7 of the 13 factors compared between the two stocks.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

About Pluri

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.